Clinical trial
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or…
NCT00410605 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00410605 |
|---|---|
| Title | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma |
| Official title | Phase II Trial of Bevacizumab Combined With Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma in Relapse, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, lenalidomide, dexamethasone |
| Enrollment | 39 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Jun 1, 2014 |
| First posted | Dec 13, 2006 |
| Last update posted | Sep 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: